ALMKT:EPA
Mauna Kea Technologies SA
€0.097
arrow_upward
+0.62%(+0.00060) 1D
Oct 30, 5:35:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
18.26M
Avg. vol.
472.04K
Volume
291.17K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
18.26M
Avg. vol.
472.04K
Volume
291.17K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
Nacionale
·
22 minutes ago
Why the stock market fell on Friday: AI spending fears hit tech, QQQ and VOO
bloomingbit
·
25 minutes ago
New York Stocks Close Lower; Nasdaq Falls 2.86%
富途牛牛
·
10 minutes ago
The Selloff in Tech Stocks Is Shifting Into Overdrive
TradingView
·
1 hour ago
Nasdaq Sinks 2%, Dow Falls 300 Points as Earnings Misses Rattle Wall Street
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA